Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Mavrilimumab (Primary)
- Indications COVID-19 pneumonia; Inflammation; Respiratory insufficiency
- Focus Therapeutic Use
- 05 Aug 2020 New trial record